Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy

Cheng, Karis Kin Fong; Lee, Vincent; Li, Chi Kong; Goggins, William C.; Thompson, David R.; Yuen, HL; Epstein, Joel B.

doi:10.1016/j.oraloncology.2010.11.019

Cited by 63 publications

(85 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathogenesis and clinical phenotype of oral mucositis caused by high‐dose chemotherapy or radiotherapy are well described in the literature 1, 2, 3, 4, 5, 6, 7, 8. In contrast, a unique manifestation of oral mucosal injury has been documented within the past 5 years in association with mammalian target of rapamycin (mTOR) inhibitors 8, 9, 10.…”

Section: Introductionmentioning

confidence: 99%

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

et al. 2016

View full text Add to dashboard Cite

In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus. This review addresses the state‐of‐the‐science regarding mTOR inhibitor‐associated stomatitis (mIAS), and delineates its clinical characteristics and management. Given the clinically impactful pain associated with mIAS, this review also specifically highlights new research focusing on the study of the molecular basis of pain. The incidence of mIAS varies widely (2–78%). As reported across multiple mTOR inhibitor clinical trials, grade 3/4 toxicity occurs in up to 9% of patients. Managing mTOR‐associated oral lesions with topical oral, intralesional, and/or systemic steroids can be beneficial, in contrast to the lack of evidence supporting steroid treatment of oral mucositis caused by high‐dose chemotherapy or radiation. However, steroid management is not uniformly efficacious in all patients receiving mTOR inhibitors. Furthermore, technology does not presently exist to permit clinicians to predict a priori which of their patients will develop these lesions. There thus remains a strategic need to define the pathobiology of mIAS, the molecular basis of pain, and risk prediction relative to development of the clinical lesion. This knowledge could lead to novel future interventions designed to more effectively prevent mIAS and improve pain management if clinically significant mIAS lesions develop.

show abstract

Section: Introductionmentioning

confidence: 99%

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Mucositis is one of the most common consequences of antineoplastic therapies [5,[25][26][27]. The higher rates of unhappiness due to "cold sores" may be associated with the fact that mucositis causes pain and discomfort and, depending on the severity, prevents patients from eating and exercising proper hygiene habits.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life of Paediatric Oncology Patients

Carneiro

Lucena²,

Ribeiro³

et al. 2016

Pesqui. bras. odontopediatria clín. integr.

View full text Add to dashboard Cite

Objective: To evaluate the indicators of quality of life (QoL) of children and adolescents with cancer and to evaluate the QoL of participants regarding oral health. Material and Methods: The modified Autoquestionnaire Qualité de Vie Enfant Imagé (AUQEI), with scores ranging from 0 to 78 and a cut-off value of 48, was the instrument used in this study. Questions were added regarding oral health, with scores ranging from 0 to 18. The study consisted of two groups: group 1 (case) consisted of 24 children and adolescents with cancer, and group 2 (control) consisted of 30 healthy children and adolescents aged 6 to 15 years old. A chi-square test was performed using the SPSS program, version 18.0, to determine whether health conditions were related to QoL. Results: We observed that 69.25% of participants had scores representing a satisfactory QoL, with a mean score of 54.3 (51.7 for the group of children and adolescents with cancer and 56.5 for the healthy group). The results of the present study showed a value of p=0.016, suggesting that the disease condition is related to lower QoL scores. The Mann-Whitney test showed that the healthy group showed significantly better indicators in the oral health domain. Conclusion: The children and adolescents under study showed satisfactory overall QoL standards; however, when comparing the cancer group to the healthy group, we observed that cancer is associated with lower QoL indicators.

show abstract

“…Oral mucositis lesions, commonly present in pediatric cancer patients 1,[7][8] , are associated with the type, dose, and administration frequency of anticancer agents [9][10] , and with factors such as neutropenia, which in general occurs about 15 days after anticancer drug admistration 1 ; this length of time coincides with the presence of oral mucositis in children and adolescents 9 .…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy-induced mucositis is one of the most important undesirable side effects of cancer treatment, promoting the worst cases of morbidity, increasing length of hospital stay, and frequently reducing the odds of controlling the tumor and the patient's life expectancy 1 .…”

Section: Introductionmentioning

confidence: 99%

Treatment of severe oral mucositis in a pediatric patient undergoing chemotherapy

Ribeiro

Valença

Bonan

2015

RGO, Rev. Gaúch. Odontol.

View full text Add to dashboard Cite

show abstract

Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy

Cited by 63 publications

References 45 publications

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

Quality of Life of Paediatric Oncology Patients

Treatment of severe oral mucositis in a pediatric patient undergoing chemotherapy

Contact Info

Product

Resources

About